Table 1.
On going targeted therapy clinical trials for breast cancer with brain metastasis
| Agent | Phase of study | Target | Clinicaltrial.gov Identification number |
|---|---|---|---|
| Lapatinib/WBRT | II | HER2 | NCT01622868 |
| ARRY-380/trastuzumab | I | HER2 | NCT01921335 |
| Bevacizumab/etoposide/cisplatin followed by WBRT | II | VEGF | NCT02185352 |
| ITC trastuzumab/ITC pertuzumab | I | HER2 | NCT02598427 |
| Cabozantinib/trastuzumab | II | HER2 | NCT02260531 |
| Lapatinib/everolimus/capecitabine | I/II | HER2/EGFR/mTOR | NCT01783756 |
| Pertuzumab/trastuzumab | II | HER2/EGFR | NCT02536339 |
| Intermittent lapatinib tandem capecitabine | I | HER2/EGFR | NCT02650752 |
| GRN1005/Trastuzumab | II | HER2 | NCT01480583 |
| Lapatinib/WBRT followed by trastuzumab | I | HER2/EGFR | NCT00470847 |
| Bevacizumab plus cisplatin/etoposide | II | VEGF-A | NCT01281696 |
| Iniparib | II | PARP | NCT01173497 |
| Sorafenib/WBRT | II | VEGFR/PDGFR/Raf | NCT01724606 |
| Lapatinib/temozolomide | I | HER2 | NCT00614978 |
| Capecitabine and buparlisib | II | PI3K | NCT02000882 |
| Tremelimumab WBRT or SRS | II | Immune checkpoint blockade | NCT02563925 |
| Neratinib and capecitabine | II | HER2/EGFR | NCT01494662 |
| Bevacizumab plus carboplatin | II | VEGF | NCT01004172 |
| Afatinib plus venorelbine | II | HER2/EGFR | NCT01441596 |
| Palbociclib | II | CDK4/6 | NCT02774681 |
| Abemacicliba | II | CDK4 | NCT02308020 |
| Durvalumaba | II | Immune checkpoint blockade | NCT02669914 |
| Vorinostata | I | Histone deacetylase | NCT00838929 |
| Bevacizumaba | II | VEGF | NCT01898130 |
Accessed on 5 July 2016 at www.clinicaltrials.gov.
WBRT, whole brain radiation therapy; SRS, stereotactic radiosurgery, ITC, intrathecal.
a
Allows for of other histological types with brain involvement other than breast cancer.